Global Financing and Long-Term Technical Assistance for Multidrug-Resistant Tuberculosis: Scaling Up Access to Treatment

PLoS Medicine

Volumn 11, Issue 9, 2014, Pages

  Hwang, Thomas J ^a,b   Keshavjee, Salmaan ^c,d  

^a HARVARD UNIVERSITY   (United States)

^b Blackstone Group   (United Kingdom)

^c HARVARD MEDICAL SCHOOL   (United States)

^d PARTNERS IN HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; CYCLOSERINE; ETHIONAMIDE; KANAMYCIN; PNEUMOCOCCUS VACCINE; PYRAZINAMIDE; TUBERCULOSTATIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CHEMOTHERAPY; COST OF ILLNESS; DRUG COST; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH CARE FINANCING; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HUMAN; MALARIA; MULTIDRUG RESISTANT TUBERCULOSIS; ECONOMICS; HEALTH; TIME; TREATMENT OUTCOME; TRENDS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; GLOBAL HEALTH; HEALTH PLANNING TECHNICAL ASSISTANCE; HEALTH SERVICES ACCESSIBILITY; HUMANS; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84907960454     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001738     Document Type: Article

References (32)

1. Keshavjee S, Farmer PE, (2010) Tuberculosis, drug resistance, and the history of modern medicine. N Engl J Med 367: 931–936.
2. World Health Organization (2009) Sixty-second World Health Assembly: Prevention and control of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. WHO/WHA62.15/Agenda N. 12.9. Geneva: WHO.
3. Keshavjee S, Farmer PE, (2010) Time to put boots on the ground: making universal access to MDR-TB treatment a reality. Int J Tuberc Lung Dis 14: 1222–1225.
4. Keshavjee S, Farmer PE, (2010) Picking up the pace–scale-up of MDR tuberculosis treatment programs. N Engl J Med 363: 1781–1784.
5. World Health Organization (2013) Global tuberculosis report 2013. WHO/HTM/TB/2013.11. Geneva: WHO.
6. Long Q, Smith H, Zhang T, Tang S, Garner P, (2011) Patient medical costs for tuberculosis treatment and impact on adherence in China: a systematic review. BMC Public Health 11: 393.
7. Sutton BS, (2010) Evaluation of the public-private mix: how economics can contribute to tuberculosis control. Expert Rev Anti Infect Ther 8: 489–491.
8. Moon S, Jambert E, Childs M, von Schoen-Angerer T, (2011) A win-win solution?: A critical analysis of tiered pricing to improve access to medicines in developing countries. Global Health 7: 39.
9. Waning B, Kyle M, Diedrichsen E, Soucy L, Hochstadt J, et al. (2010) Intervening in global markets to improve access to HIV/AIDS treatment: an analysis of international policies and the dynamics of global antiretroviral medicines markets. Global Health 6: 9.
10. Gupta R, Cegielski JP, Espinal MA, Henkens M, Kim JY, et al. (2002) Increasing transparency in partnerships for health–introducing the Green Light Committee. Trop Med Int Health 7: 970–976.
11. Stop TB Partnership, World Health Organization. (2009) The Global Drug Facility: Comparative advantages. WHO/HTM/STB/2009.56. Geneva: WHO.
12. Gupta R, Kim JY, Espinal MA, Caudron JM, Pecoul B, et al. (2001) Responding to market failures in tuberculosis control. Science 293: 1049–1051.
13. Institute of Medicine (2012) Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis - Workshop Summary. Washington, D.C.: The National Academies Press.
14. Medecins sans Frontieres and the International Union Against Tuberculosis and Lung Disease (2012) DR-TB drugs under the microscope: Sources and prices for drug-resistant tuberculosis medicines. Geneva: WHO.
15. Pooran A, Pieterson E, Davids M, Theron G, Dheda K, (2013) What is the cost of diagnosis and management of drug resistant tuberculosis in South Africa? PLoS ONE 8: e54587.
16. Hwang TJ, Wares DF, Jafarov A, Jakubowiak W, Nunn P, et al. (2013) Safety of cycloserine and terizidone for the treatment of drug resistant tuberculosis: a meta-analysis. Int J Tuberc Lung Dis 17: 1257–1266.
17. Nathanson E, Gupta R, Huamani P, Leimane V, Pasechnikov AD, et al. (2004) Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis 8: 1382–1384.
18. Hwang TJ, Dotsenko S, Jafarov A, Weyer K, Falzon D, et al. (2014) Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies. BMJ Open 4: e004143.
19. Barder O, Kremer M, Levine R (2005) Making markets for vaccines: Ideas to action. Washington, D.C.: Center for Global Development.
20. GAVI Alliance Revised Co-financing Policy (2010) Geneva: GAVI Alliance. Available: http://www.gavialliance.org/library/gavi-documents/policies/gavi-alliance-revised-co-financing-policy. Accessed 20 August 2014.
21. Snyder CM, Begor W, Berndt ER, (2011) Economic perspectives on the advance market commitment for pneumococcal vaccines. Health Aff (Millwood) 30: 1508–1517.
22. Berman D, Malpani R, (2011) High time for GAVI to push for lower prices. Hum Vaccin 7: 290.
23. The Global Fund to Fight AIDS, Tuberculosis, and Malaria (2014) Grant Portfolio: Performance and Data. Available: http://portfolio.theglobalfund.org/en/Home/Index. Accessed 6 May 2014.
24. Atun R, Weil DE, Eang MT, Mwakyusa D, (2010) Health-system strengthening and tuberculosis control. Lancet 375: 2169–2178.
25. Miller TL, McNabb SJ, Hilsenrath P, Pasipanodya J, Weis SE, (2009) Personal and societal health quality lost to tuberculosis. PLoS ONE 4: e5080.
26. UNITAID (2014) MDR-TB Strategic Rotating Stockpile. Available: http://www.unitaid.eu/en/mdr-tb-strategic-rotating-stockpile. Accessed 15 June 2014.
27. Merson MH, Curran JW, Griffith CH, Ragunanthan B, (2012) The President's Emergency Plan for AIDS Relief: from successes of the emergency response to challenges of sustainable action. Health Aff (Millwood) 31: 1380–1388.
28. Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, et al. (2009) The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 360: 2397–2405.
29. Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, et al. (2012) Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 366: 2151–2160.
30. Hwang TJ, Carpenter D, Kesselheim AS, (2014) Target small firms for antibiotic innovation. Science 344: 967–969.
31. Lindor RA, Allocco SJ, Cheatham L, Cortese DA, Hall RF, et al. (2013) Regulatory and reimbursement innovation. Sci Transl Med 5: 176cm3.
32. Institute of Medicine (2008) Partners in Health White Paper—Stemming the Tide of Multidrug-Resistant Tuberculosis: Major Barriers to Addressing the Growing Epidemic. Washington, D.C.: National Academies Press.